and adolescents aged 12 years and older with chronic spontaneous urticaria FDA approvals, PDUFA dates and pipeline.
Updated Snapshot 20261116T112050ZBuilt
We track 1 and adolescents aged 12 years and older with chronic spontaneous urticaria drug. No FDA approvals recorded yet. 1 of 1 PDUFA decisions (100%) were approvals.
Drugs
| Drug | Sponsor | Modality | Designations |
|---|---|---|---|
| Dupixent (dupilumab) | REGN | antibody | Orphan Drug, Priority Review |
Upcoming catalysts
No events in this view.
Past catalysts and decisions
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| April 18, 2025 | Dupixent (dupilumab) | REGN | PDUFA date | and adolescents aged 12 years and older with chronic spontaneous urticaria | Approved | SEC 8-K Exhibit 99.1 |
All indications · Approval rates by indication
Not submitted to search engines: Needs 2 drugs and 3 sourced events; has 1 and 1.
Questions
What and adolescents aged 12 years and older with chronic spontaneous urticaria drugs have upcoming PDUFA dates?
None disclosed.
Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.